This inventor holds 1 USPTO granted patent. Top assignee: Washington University. Active years: 2026.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2026
Title: Nicholas Semenkovich and a Patent for Risk-Stratifying Lung Cancer Patients.
Introduction
Nicholas Semenkovich is an inventor associated with St. Louis, Missouri. His patent work addresses the use of cell-free DNA liquid biopsies to help assess risk among patients with oligometastatic non-small cell lung cancer.
Latest Patents
Semenkovich is credited with 1 patent: “Method to Risk-Stratify Oligometastatic Non-Small Cell Lung Cancer Patients Using Cell-Free DNA Liquid Biopsies.” The invention focuses on applying liquid-biopsy data to patient risk stratification.
Career Highlights
Semenkovich is associated with Washington University. His listed patent reflects work at the intersection of cancer research and diagnostic methods.
Collaborations
The patent’s association with Washington University connects the invention to the university’s research environment. The provided information does not identify additional collaborators.
Conclusion
Nicholas Semenkovich’s patent applies cell-free DNA liquid biopsies to risk stratification for patients with oligometastatic non-small cell lung cancer.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile